surgery-anesthesia-euro-gastro-congress-2018-posters

Page 48

N o v e m b e r 1 2 - 1 3 , 2 0 1 8 | R o m e , I t a l y

Joint Event on

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Surgery and Anesthesia 2018 & Euro Gastro Congress 2018

Case Reports in Surgery and Invasive Procedures

Volume 2

GASTROENTEROLOGY

International Conference on

SURGERY AND ANESTHESIA

International Conference on

Case Rep Surg Invasive Proced 2018, Volume 2

THE EFFICACY OF TOCOTRIENOLS IN THE TREATMENT OF NON-

ALCOHOLIC STEATOHEPATITIS: A SYSTEMATIC REVIEW

Higinio T Mappala

Jose Reyes Mem. Medical Centre Manila, Philippines

Introduction:

Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may prog-

ress to non-alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modifi-

cation through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far

been approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components

of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias. Other interventions are directed at specific path-

ways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, pro-inflammatory cytokines,

apoptosis, bacterial overgrowth, and angiotensin pathway.

Objective:

This lecture aims to show the potential of tocotrienols as a promising therapeutic option for NAFLD.

Method:

This is a systematic review of randomized controlled trials on the effects of Tocotrienols on non-alcoholic fatty liver dis-

ease. (NAFLD)

Conclusion:

Tocotrienols may yet prove to be an effective treatment for non-alcoholic fatty liver disease.